Prospective Grant of Start-Up Exclusive Evaluation Option License: Methods of Treating Giardiasis Using Available Compounds, 42532 [2013-16948]

Download as PDF 42532 Federal Register / Vol. 78, No. 136 / Tuesday, July 16, 2013 / Notices their retinal illumination output) and will accept a near IR CCD camera connected to a TV mounted on the photographic-camera port. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license may be granted unless, within fifteen (15) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: July 9, 2013. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 2013–16950 Filed 7–15–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Start-Up Exclusive Evaluation Option License: Methods of Treating Giardiasis Using Available Compounds AGENCY: National Institutes of Health, HHS. ACTION: Notice. This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a start-up exclusive evaluation option license to practice the inventions embodied in U.S. provisional Applications 61/392,096 (E–211–2010/ 0–US–01) filed October 12, 2010 and 61/411,509 filed November 9, 2010 (E– 211–2010/1–US–01); PCT application No. PCT/US2011/055902 filed October 12, 2011 (E–211–2010/2–PCT–01); US patent application No. 13/878,832 filed April 11, 2013 (E–211–2010/2–US–06); European patent application No. 11773158.8 filed May 2, 2013 (E–211– 2010/2–EP–04); Canadian application No. 2,814,694 filed April 11, 2013 (E– emcdonald on DSK67QTVN1PROD with NOTICES SUMMARY: VerDate Mar<15>2010 18:49 Jul 15, 2013 Jkt 229001 211–2010/2–CA–03); Australia application No. 2011316657 filed April 12, 2013 (E–211–2010/2–AU–02); and Indian application No. 1137/KOLNP/ 2013 filed April 22, 2013 (E–211–2010/ 2–IN–05); each entitled ‘‘Methods of Treating Giardiasis’’ by Wei Zheng et al. to BrioMed, Inc., having a place of business at 1743 S. Westgate Ave, Los Angeles, CA 90025 USA. The patent rights in this invention have been assigned to the United States of America and the University of Maryland. DATES: Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before July 31, 2013 will be considered. ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Tedd Fenn, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Email: Tedd.Fenn@mail.nih.gov; Telephone: 301–435–5031; Facsimile: 301–402– 0220. SUPPLEMENTARY INFORMATION: The prospective start-up exclusive evaluation option license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective start-up exclusive evaluation option license may be granted unless, within fifteen (15) days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. This technology includes a group of at least twenty-nine, diverse, commercially available compounds that are newly identified for activity against Giardia lamblia parasites. At least six of the candidate compounds, Bortezomib, Decitabine, Hydroxocobalamin, Amlexanox, Idarubicin, and Auranofin have preexisting FDA approval for human use for other (non-Giardia) conditions. Another three compounds, Fumagillin, Nitarsone and Carbadox have preexisting approval for veterinary use for non-Giardia conditions. Additional active compounds identified include: Acivicin, Riboflavin butyrate, BTO–1, GW9662, Dinitroph-dfgp, Deserpidine, Tetramethylthiuram disulsulfide, Disulfiram, Mitoxantrone, Ecteinascidin 743, 17allyaminogeldanamycin, Carboquone and Nocodazole. The anti-Giardial activity of these compounds presents a cost saving opportunity for the rapid development of new, better tolerated PO 00000 Frm 00047 Fmt 4703 Sfmt 4703 treatments for the most prevalent human intestinal parasite infection in the United States and the world. The proposed field of exclusivity may be limited to therapeutics for treatment of Giardia infection in mammals. Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. Dated: July 9, 2013. Richard U. Rodriguez, Director, Division of Technology Development and Transfer, Office of Technology Transfer. [FR Doc. 2013–16948 Filed 7–15–13; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HOMELAND SECURITY Cooperative Research and Development Agreement (CRADA) Opportunity With the Department of Homeland Security for the Development of a Foot-and-Mouth Disease 3ABC ELISA Diagnostic Kit; Correction Science and Technology Directorate, Plum Island Animal Disease Center, Department of Homeland Security. ACTION: Notice of intent; correction. AGENCY: The Department of Homeland Security Science and Technology Directorate (DHS S&T), through its Plum Island Animal Disease Center (PIADC), published a document in the Federal Register of May 16, 2013, seeking industry collaborators to aid DHS S&T in developing and validating an ELISA diagnostic kit for detection of Foot and Mouth Disease Virus (FMDV) nonstructural proteins. The document did not specify dates for when the submission of proposals are due. FOR FURTHER INFORMATION CONTACT: Angela Ervin, 202–254–5624. SUMMARY: Correction In the Federal Register of May 16, 2013, in FR Doc. DHS–2013–0036, on page 1, in the third column, correct the DATES caption to read: DATES: Submit proposals on or before August 8, 2013. Correction In the Federal Register of May 16, 2013, in FR Doc. DHS–2013–0036, on E:\FR\FM\16JYN1.SGM 16JYN1

Agencies

[Federal Register Volume 78, Number 136 (Tuesday, July 16, 2013)]
[Notices]
[Page 42532]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-16948]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Start-Up Exclusive Evaluation Option 
License: Methods of Treating Giardiasis Using Available Compounds

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
part 404, that the National Institutes of Health (NIH), Department of 
Health and Human Services, is contemplating the grant of a start-up 
exclusive evaluation option license to practice the inventions embodied 
in U.S. provisional Applications 61/392,096 (E-211-2010/0-US-01) filed 
October 12, 2010 and 61/411,509 filed November 9, 2010 (E-211-2010/1-
US-01); PCT application No. PCT/US2011/055902 filed October 12, 2011 
(E-211-2010/2-PCT-01); US patent application No. 13/878,832 filed April 
11, 2013 (E-211-2010/2-US-06); European patent application No. 
11773158.8 filed May 2, 2013 (E-211-2010/2-EP-04); Canadian application 
No. 2,814,694 filed April 11, 2013 (E-211-2010/2-CA-03); Australia 
application No. 2011316657 filed April 12, 2013 (E-211-2010/2-AU-02); 
and Indian application No. 1137/KOLNP/2013 filed April 22, 2013 (E-211-
2010/2-IN-05); each entitled ``Methods of Treating Giardiasis'' by Wei 
Zheng et al. to BrioMed, Inc., having a place of business at 1743 S. 
Westgate Ave, Los Angeles, CA 90025 USA. The patent rights in this 
invention have been assigned to the United States of America and the 
University of Maryland.

DATES: Only written comments and/or application for a license that are 
received by the NIH Office of Technology Transfer on or before July 31, 
2013 will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, 
comments and other materials relating to the contemplated license 
should be directed to: Tedd Fenn, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, MD 20852-3804; Email: Tedd.Fenn@mail.nih.gov; Telephone: 
301-435-5031; Facsimile: 301-402-0220.

SUPPLEMENTARY INFORMATION: The prospective start-up exclusive 
evaluation option license will be royalty bearing and will comply with 
the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404. The 
prospective start-up exclusive evaluation option license may be granted 
unless, within fifteen (15) days from the date of this published 
Notice, NIH receives written evidence and argument that establishes 
that the grant of the license would not be consistent with the 
requirements of 35 U.S.C. 209 and 37 CFR part 404.
    This technology includes a group of at least twenty-nine, diverse, 
commercially available compounds that are newly identified for activity 
against Giardia lamblia parasites. At least six of the candidate 
compounds, Bortezomib, Decitabine, Hydroxocobalamin, Amlexanox, 
Idarubicin, and Auranofin have preexisting FDA approval for human use 
for other (non-Giardia) conditions. Another three compounds, 
Fumagillin, Nitarsone and Carbadox have preexisting approval for 
veterinary use for non-Giardia conditions. Additional active compounds 
identified include: Acivicin, Riboflavin butyrate, BTO-1, GW9662, 
Dinitroph-dfgp, Deserpidine, Tetramethylthiuram disulsulfide, 
Disulfiram, Mitoxantrone, Ecteinascidin 743, 17-allyaminogeldanamycin, 
Carboquone and Nocodazole. The anti-Giardial activity of these 
compounds presents a cost saving opportunity for the rapid development 
of new, better tolerated treatments for the most prevalent human 
intestinal parasite infection in the United States and the world.
    The proposed field of exclusivity may be limited to therapeutics 
for treatment of Giardia infection in mammals.
    Properly filed competing applications for a license filed in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection, and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: July 9, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer.
[FR Doc. 2013-16948 Filed 7-15-13; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.